Marker Therapeutics has treated the first patient in its Phase II trial of its lead MultiTAA-specific T cell product candidate MT-401 in patients with acute myeloid leukaemia (AML).

The multi-center trial will have 160 patients with AML following an allogeneic stem cell transplant in both the adjuvant, as well as active disease settings.

In the trial, 120 patients will be enrolled in the adjuvant disease group who are randomised into a 1:1 ratio to either receive MT-401 at 90 days post-transplant or standard of care (observation).

About 40 subjects with active disease will be given MT-401 as part of the single-arm group.

Marker noted that the trial will be carried out at 20 top cancer centres across the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Analysis of relapse-free survival (RFS) in the adjuvant arm and determining complete remission rate and duration of complete remission in active disease patients will form the trial’s primary objectives.

For the adjuvant arm, overall survival and graft-versus-host disease relapse-free survival will be the additional objectives while overall response rate, duration of response, progression-free survival and overall survival will be included as the additional objectives for the active disease group.

Marker Therapeutics chief medical officer Mythili Koneru said: “We are pleased to have dosed the first patient with MT-401 in our company-sponsored clinical trial, particularly in a patient population in which there remains a critical unmet need.

“In various investigator-sponsored Phase I trials at the Baylor College of Medicine, our MultiTAA-specific T cell therapies have been generally well-tolerated and demonstrated durable anti-cancer responses across a broad range of cancers, including post-transplant AML.

“Based on these results, we believe that MT-401 has the potential to become a meaningful treatment option for patients suffering from this disease.”

Topline data readout of active disease group is anticipated in the first quarter of next year.